美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Invea Therapeutics, Inc.

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：0.00

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Invea Therapeutics, Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.inveatx.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Invea Therapeutics, Inc.于2021年10月20日根据特拉华州法律成立。该公司是一家生物技术公司，专注于开发用于免疫介导的炎症性疾病（IMIDs）的口服小分子疗法。目前，该公司有两个候选产品：INVA8001，旨在治疗慢性诱发性荨麻疹，以及INVA8003，他处于早期临床前开发阶段，在各种IMID中有更广泛的应用。INVA8001计划在欧盟推进2a期临床开发。通过采用AlphaMeld平台，该平台集成了人工智能和机器学习等先进技术，该公司旨在识别和开发安全、有效的口服疗法，不仅可以解决炎症问题，还可以提高IMID患者的生活质量。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/INAI/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAI\",,,,,undefined,":{"symbol":"INAI","market":"US","secType":"STK","nameCN":"Invea Therapeutics, Inc.","latestPrice":0,"timestamp":0,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘后交易","change":0,"latestTime":"02-23 16:28:41 EST","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAI\",,,,,undefined,":{"symbol":"INAI","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INAI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INAI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inveatx.com","compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Invea Therapeutics, Inc.于2021年10月20日根据特拉华州法律成立。该公司是一家生物技术公司，专注于开发用于免疫介导的炎症性疾病（IMIDs）的口服小分子疗法。目前，该公司有两个候选产品：INVA8001，旨在治疗慢性诱发性荨麻疹，以及INVA8003，他处于早期临床前开发阶段，在各种IMID中有更广泛的应用。INVA8001计划在欧盟推进2a期临床开发。通过采用AlphaMeld平台，该平台集成了人工智能和机器学习等先进技术，该公司旨在识别和开发安全、有效的口服疗法，不仅可以解决炎症问题，还可以提高IMID患者的生活质量。","exchange":"NASDAQ","name":"Invea Therapeutics, Inc.","nameEN":"Invea Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INAI\",market:\"US\",,,undefined,":null}}